Mohammed Masri, MD
Hematology & Oncology · Mount Clemens, MINPI 1669409439
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,730 of the $12,333 with a category attached, or 70.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 16.4%.
Across 520 payments — averaging $23.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Genentech USA, Inc.$904
- Novartis$870
- Johnson & Johnson$618
- Astellas Pharma US Inc$598
- Lilly USA, LLC$491
- plus $7K from 54 others
Across 60 payments — averaging $3170.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$93K
- Eli Lilly$42K
- Merck$23K
- Bristol Myers Squibb$21K
- Helsinn Healthcare SA$11K
- Pharmacyclics LLC, An Abbvie Company$2K
Across 4 payments — averaging $12,500 each. An ownership or investment interest held by the physician or an immediate family member.
- Valencia Technologies Corporation$50K
What the payments were for
- Consulting fees$1,95016%
- Food & beverage$8,73071%
- Education$1,65213%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis SurgiClose$561
- VERZENIO$210
- Kerecis GraftGuide$140
How this compares
$12,333 in reported general payments places this provider in the 85th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 28 | $397,197 |
| ImbruvicaIbrutinib | 18 | $279,887 |
| XtandiEnzalutamide | 22 | $270,211 |
| BrukinsaZanubrutinib | 12 | $107,737 |
| EliquisApixaban | 51 | $50,431 |
| Anastrozole | 55 | $3,536 |
| Megestrol Acetate | 17 | $2,383 |
| Potassium Chloride | 33 | $515 |
| Levothyroxine Sodium | 37 | $464 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 25 | $410 |
| Dexamethasone | 16 | $264 |
| Omeprazole | 19 | $233 |
| Hydroxyurea | 11 | $224 |
| Pantoprazole Sodium | 30 | $190 |
| Alprazolam | 25 | $156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $360 | $397,19728 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $232 | $279,88718 claims |
| Astellas Pharma US IncXtandi | $598 | $270,21122 claims |
| Beigene USA, Inc.Brukinsa | $54 | $107,73712 claims |
| PfizerEliquis | $218 | $50,43151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Mount Clemens
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
- Hadeel AssadDetroit$80K
- Andrew MuskovitzSouthfield$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.